Better Context → Better Decisions
Context counts in life sciences. The Celltelligence analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access can use our library to search all of the content already delivered to their inbox. If you think a colleague would enjoy receiving our content, reach out to the Celltelligence team to make it happen.
Free
Posted in: Allogeneic, Autologous, BCMA, CAR-T, CD19 Jan 10 | 2022Allogene's FDA Clinical Hold Lifted; JPM 2022 Day 1: BMS, Novartis, JNJ, and GileadAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T, CD19 Dec 17 | 2021Kymriah Absent From December’s CHMP HighlightsAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Dec 17 | 2021Daiichi Sankyo Authorizes Yescarta’s First Treatment Center in Japan 11 Months After ApprovalAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Dec 14 | 2021Novartis May Apply Learnings from BELINDA’s Failure to YTB323 in 2L DLBCL; How Could Novartis Position Their Novel T-Charge Manufacturing Platform in 2L DLBCL and MM Settings? Yescarta's ZUMA-12 Demonstrates an 89% ORR in 1L DLBCL; ASH 2021 Day 3Access Free BlastFree
Posted in: Autologous, BCMA Dec 14 | 2021CARTITUDE-1 and CARTITUDE-2 Study Updates; Carvykti Improves Clinical Outcomes Compared to Real-World Clinical Practice in R/R MM; ASH 2021 Day 3 Legend Investor EventAccess Free BlastFree
Posted in: Allogeneic, BCMA, CAR-T, CD19 Dec 14 | 2021Could ALLO-715 Compete or Complement Carvykti / Abecma? ASH 2021 Day 3 Allogene Investor EventAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19, CD22 Dec 13 | 2021Autolus’s Industrialized Manufacturing Process for Obe-cel; Updated Results From Autolus’s Ph1 ALLCAR19 and Ph1 CARPALL Trials; ASH 2021 Day 3 Autolus Investor EventAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T, CD19 Dec 13 | 2021Will Kymriah Receive a CHMP Positive Opinion in R/R FL This Week? Carvykti’s CHMP Opinion Likely to Occur by February 2022; Tecartus and Breyanzi Continue to Experience Delays; December’s CHMP AgendaAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T Dec 13 | 2021Will a KarMMa Data Cut Help Abecma's Successor Products? Safety and Efficacy Updates From bb21217’s Ph1 CRB-402 Study; Carvykti’s CARTITUDE-1 Continues Demonstrating Positive Clinical Results; ASH 2021 Day 2 Part 1Access Free BlastFree
Posted in: Autologous, CAR-T, CD19 Dec 12 | 2021The Race to 2L DLBCL: Breyanzi’s Ph3 TRANSFORM Trial vs Yescarta’s Ph3 ZUMA-7 Study; Can BMS Shift Toward Outpatient CD19 CAR-T Administration? ASH 2021 Day 1 Part 2Access Free BlastFree
Posted in: Allogeneic, BCMA, CAR-T, CD19 Dec 12 | 2021Precision’s PBCAR0191 to Target Autologous CD19 CAR-T Relapsed Patients; PBCAR269A to Be Used with Nirogacestat; ASH 2021 Day 1 Precision Investor EventAccess Free BlastFree
Posted in: Allogeneic, Autologous, CAR-T, CD19, CD22 Dec 11 | 2021Could Autolus’s AUTO1/22 Novel CD22 Binder Avoid Antigen-Related Relapse in ALL? Updated Results from Cellectis’s UCART22 Ph1 BALLI-01 Trial; Yescarta’s Ph2 ZUMA-5 Trial Continues to Demonstrate Positive Long-Term Results; ASH 2021 Day 1 Part 1Access Free BlastFree
Posted in: Autologous, BCMA, CAR-T Dec 07 | 2021Will Abecma Receive Approval in Japan by January 2022? Could JNJ / Legend’s Carvykti be Approved by September 2022?Access Free BlastFree
Posted in: Autologous, BCMA Dec 06 | 2021JNJ / Legend Files Carvykti in Japan for R/R MMAccess Free BlastFree
Posted in: Autologous, BCMA, CD19 Dec 02 | 2021Novartis’s T-Charge Platform Reduces CAR-T Manufacturing to 2 Days; Novartis's R&D Day SummaryAccess Free BlastFree
Posted in: Autologous, CAR-T Dec 01 | 20212seventy’s SC-DARIC33 IND Cleared by the FDA for R/R Pediatric AML; 2seventy Q3 2021 Earnings SummaryAccess Free BlastFree
Posted in: Allogeneic, CAR-T Nov 19 | 2021Cellectis - Cytovia Partnership Expands to Include ChinaAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T Nov 18 | 2021Cilta-cel to be Commercialized as Carvykti Upon FDA Approval; JNJ Highlights Innovative Manufacturing and Supply System for Carvykti; How Quickly Could Carvykti Move Into Earlier Lines? JNJ’s Business Review Event 2021Access Free BlastFree
Posted in: Autologous, BCMA, CAR-T Nov 17 | 2021When Could Legend File Cilta-cel in 2L MM? Legend to Submit an NDA to Japan’s PMDA for Cilta-cel in R/R MM by YE 2021; Legend Develops a Novel Tri-Specific CAR-T; Legend Q3 2021 Earnings SummaryAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Nov 15 | 2021William Young Appointed as a Non-Executive Director of Autolus’s Board of DirectorsAccess Free BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.